Tiredness; COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Tiredness) and COVID-19 (COVID-19) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Plaque psoriasis.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form and third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In 2021, the patient experienced COVID-19 (COVID-19). On an unknown date, the patient experienced FATIGUE (Tiredness). At the time of the report, FATIGUE (Tiredness) was resolving and COVID-19 (COVID-19) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported.  It was unknown if patient was enrolled in a COVID-19 vaccine trial.  No treatment medication was reported.  Company Comment: This spontaneous case concerns a 69-year-old, male patient with history of co-suspect administration of Humira (adalimumab) for Moderate-to-Severe Chronic Plaque Psoriasis, who experienced the unexpected, non-serious of COVID-19 and the expected, non-serious event of fatigue. The event COVID-19 occurred on an unspecified date in 2021 after receiving the first dose of the mRNA-1273 vaccine. The start date of the event fatigue was not provided. It was reported that after vaccination, the patient felt a little tired. It was also reported that he experienced COVID-19 and thought that he may come down with something but was not sure what it was. No further details were provided. The outcome of the event COVID-19 was unknown while the event fatigue was resolving at the time of the report. The patient's advanced age (high risk for infections) remains a confounder. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 69-year-old, male patient with history of co-suspect administration of Humira (adalimumab) for Moderate-to-Severe Chronic Plaque Psoriasis, who experienced the unexpected, non-serious of COVID-19 and the expected, non-serious event of fatigue. The event COVID-19 occurred on an unspecified date in 2021 after receiving the first dose of the mRNA-1273 vaccine. The start date of the event fatigue was not provided. It was reported that after vaccination, the patient felt a little tired. It was also reported that he experienced COVID-19 and thought that he may come down with something but was not sure what it was. No further details were provided. The outcome of the event COVID-19 was unknown while the event fatigue was resolving at the time of the report. The patient's advanced age (high risk for infections) remains a confounder. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.